Liminatus Pharma LLCLIMN
13F holders, Q2 2025 (June 30)10holders
$11.15avg. 13F price*
At the end of Q2 2025, 10 institutions reported holding Liminatus Pharma LLC (LIMN) in their 13F filings. The largest holders were Vanguard Group Inc. ($819K), Geode Capital Management, LLC ($712K) and UBS Group AG ($351K).
- Company
- Liminatus Pharma LLC
- CUSIP
- 53271X108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 10 | $2.3M |
| Exits | 0 | $0 |
Ownership 10 holders
| Vanguard Group Inc. | 0.00% | New | 73,424 | $819K |
| Geode Capital Management, LLC | 0.00% | New | 63,841 | $712K |
| UBS Group AG | 0.00% | New | 31,486 | $351K |
| State Street Corp. | 0.00% | New | 19,000 | $212K |
| BlackRock, Inc. | 0.00% | New | 13,255 | $148K |
| Royal Bank of Canada | 0.00% | New | 2,886 | $32K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 508 | $6K |
| Barclays PLC | 0.00% | New | 184 | $2K |
| Bank of America Corp. | 0.00% | New | 66 | $735 |
| SBI Securities Co., Ltd. | 0.00% | New | 52 | $580 |
"% of holder's portfolio" is LIMN's weight in each manager's 13F, not the share of Liminatus Pharma LLC the manager owns.